StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a report released on Wednesday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Several other research firms have also recently issued reports on RVNC. William Blair reissued…
